Selinexor, pegaspargase, and dexamethasone for NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with NK/T-cell lymphoma confirmed by a tissue sample taken within the last 3 months.
- Your lymphoma is stage 1 or 2 and you have at least one tumor that can be measured.
- You have not received any prior cancer treatment (like chemotherapy, radiation, or immunotherapy).
- Your blood counts and liver and kidney function are within acceptable limits.
- You are willing to use effective birth control during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests a combination of three drugs (selinexor, an anti-PD-1 antibody, and golidocitinib) for patients with relapsed or refractory NKTCL. The goal is to see if this combination can effectively treat the lymphoma and improve outcomes.
This trial is testing a combination of three treatments for a rare type of lymphoma called NKTCL that has come back or not responded to prior therapy. The treatments include a pill (selinexor), an immune-boosting drug (anti-PD-1 antibody), and a chemotherapy combination (P-GemOx). The goal is to see if this combination can help control the lymphoma and improve outcomes.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
Hear when a new NKTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.